Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,068 across all filing types
Latest filing 2023-03-24 Regulatory Filings
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Vivesto and Elevar seek to transfer Elevar’s Apealea rights and obligations to a third party
Regulatory Filings Classification · 99% confidence The document discusses a potential transfer of commercialization rights for a product (Apealea) and the resulting financial impact (impairment charge/write-down) that will be included in the 2022 annual report, which is expected in April 2023. The text itself is an announcement made on March 24, 2023, concerning corporate strategy and financial adjustments related to an ongoing partnership issue. It is not the full Annual Report (10-K), an Earnings Release (ER), or a Call Transcript (CT). Since it details significant corporate events, management commentary, and financial adjustments outside of a standard quarterly report, it most closely aligns with a general corporate announcement or regulatory filing that doesn't fit a more specific category like M&A (TAR) or Director's Dealing (DIRS). Given the nature of the announcement (strategic partnership change and related write-downs), and the fact that it is a formal disclosure under EU Market Abuse Regulation, the most appropriate general category is Regulatory Filings (RNS), as it is a specific, material event disclosure that isn't covered by the other specialized codes.
2023-03-24 English
Vivesto och Elevar avser överlåta Elevars rättigheter och skyldigheter för Apealea till tredje part
Legal Proceedings Report Classification · 99% confidence The document is a press release dated March 24, 2023, announcing that Elevar Therapeutics intends to transfer its rights and obligations for the product Apealea to a third party. It discusses the potential impact on Vivesto, including a preliminary write-down of assets (190 MSEK total, detailed later as 180 MSEK + 10 MSEK) which will be included in the 2022 annual report to be published in April 2023. The text is a direct announcement of a significant business/licensing event and a related accounting adjustment. It is not a full Annual Report (10-K), an Earnings Release (ER), or a Call Transcript (CT). Since it details a significant business development, potential asset impairment, and is presented as a formal announcement (indicated by the closing statement regarding MAR disclosure obligations and the attached PDF link), it fits best as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the transfer is viewed as a structural change, but RNS is the most appropriate general category for material, non-standardized announcements not covered by other specific codes (like DIV, DIRS, etc.). Given the nature of the announcement (licensing/asset transfer discussion), RNS is the safest classification as it is a material event disclosure.
2023-03-24 Swedish
Earnings Release 2022
Earnings Release Classification · 98% confidence The document is titled "Bokslutskommuniké för räkenskapsåret 1 januari – 31 december 2022" (Year-end report communication for the fiscal year January 1 – December 31, 2022). It contains detailed financial figures for the fourth quarter and the full fiscal year, including net sales, operating result, net result after tax, and earnings per share. It also includes a CEO's statement discussing business strategy and pipeline updates. This structure—a summary of financial results for a full fiscal year, often released before the full 10-K—is characteristic of an Earnings Release (ER) or a preliminary Annual Report summary. Since it provides the full year's financial summary and commentary, it aligns best with the 'Earnings Release' (ER) category, which covers the initial announcement of periodical financial results (in this case, the annual results). It is not the comprehensive 10-K, nor is it a short announcement of a report (RPA/RNS). Q4 2022
2023-02-23 Swedish
Audit Report / Information 2022
Audit Report / Information Classification · 98% confidence The document explicitly states it is the "Year-end report for the financial year January 1 – December 31, 2022". It contains detailed financial figures for the Fourth Quarter and the full Financial Year, a CEO Review, and extensive sections on products, technology, and partnerships. This structure and content strongly indicate a comprehensive annual financial report. Although it is not explicitly labeled '10-K' (which is the SEC filing equivalent), in the context of general corporate filings, a detailed 'Year-end report' that includes full financial statements and management discussion aligns best with the definition of an Annual Report (AR) or, more specifically given the context of comprehensive yearly reporting, the 10-K category, which covers official yearly reports. Since the provided definitions include 'Annual Report (Code: 10-K)' for official yearly reports covering full financial performance, this is the most appropriate classification. The document length is substantial (78,921 chars), ruling out RPA/RNS based on the 'MENU VS MEAL' rule. FY 2022
2023-02-23 English
Vivesto meddelar att Erik Kinnman tillträder sin VD befattning i januari
Board/Management Information Classification · 100% confidence The document is a press release dated December 28, 2022, announcing that Erik Kinnman will assume the role of permanent CEO starting January 23, 2023. It details his background and includes quotes from the Chairman and the incoming CEO regarding the company's future. This content directly relates to changes in senior management personnel. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short (3129 chars) and it is a direct announcement, not a report itself.
2022-12-28 Swedish
Vivesto announces Erik Kinnman to take up CEO position in January
Board/Management Information Classification · 100% confidence The document is a press release from Vivesto AB announcing that Erik Kinnman will take up the CEO position starting January 23, 2023. This announcement concerns a change in senior management. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is short and clearly communicates this management change, making MANG the most appropriate classification.
2022-12-28 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.